At the maintenance dose of 2.4mg, it lasts barely two weeks
Possible Clinical Applications for ALS Patients Greater certainty in diagnosis of ALS, in combination with other clinical measures (e.g., ALSFRS-R score) Faster diagnosis of early-stage ALS, allowing for a decreased time period between symptom onset and initiation of treatment Monitoring of disease progression over time Un-biased efficacy assessment of approved therapeutics (Edaravone and Riluzole) and pre-clinical/clinical therapeutics that work to reduce extracellular glutamate Real-time results on the efficacy of pre-clinical and clinical therapeutics, leading to faster screenings of early stage candidates and reductions in failed late-stage candidates

For example, researchers from a 2016 review of data on the gut-brain axis and BPC-157 explain that the peptide could maintain gastrointestinal mucosa, modulate serotonergic and dopaminergic systems, regenerate peripheral nerves, protect certain neurons, counteract various types of lesions, promote wound healing, and more.7 Some of these possible benefits are due to BPC-157s promotion of the cell migration of vascular endothelial cells.24 This means that the peptide can encourage the formation of new blood vessels (also known as angiogenesis)
It directly neutralizes persistent organic pollutants and promotes their excretion from the body [1]
in the process, glutathione is converted to its oxidized form, glutathione disulfide (GSSG, also called L-()-glutathione)
(2) These two proteins can cause problems when they get out of control